Navigation Links
Ultraview SL 3800

ProductsUltraview SL 3800
Company Spacelabs Medical
Item Ultraview SL 3800
Features 
  • Default alarm limits and customizable parameter settings
  • Modular, scalable architecture
  • Compatible with Ultraview®, Ultraview SL and PCMS™ monitors and modules
  • Capability for configuring as a bedside monitor
  • Alarm limit review provides a printable summary of alarm limits for all active parameters
  • Flexport® system interfaces link alarms from standalone devices at the bedside
  • Tone access controls
  • Alarm watch delivers bed-to-central alarm notification
  • Centrally view, control, review and record patient data for all monitored patients
  • WinDNA
  • Intesys Clinical Suite (ICS) provides enterprise solutions for Full Disclosure, Electronic Flowsheet and network laser printing
  • HL7 interfaces to HIS applications
Description Ultraview SL 3800
Info Spacelabs Medical
Customer Service: (800) 522-7025
Web site: http://www.spacelabs.com/

Related medicine products :

1. Ultraview 1700 Central Monitor
2. Ultraview® Digital Telemetry
TAG: Ultraview
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2